Introduction
Matrix metalloproteinases (MMPs) are a group of zincand calcium-dependent enzymes that are implicated in the destruction of articular cartilage and bone in rheumatoid arthritis (RA). 1 One of the most abundant MMPs found in synovium and synovial fluids from RA patients is MMP-3 (stromelysin-1). 2, 3 The enzyme is found mainly as the inactive precursor proMMP-3, which may be activated by cysteine and serine proteinases, and membrane-type MMPs. 4, 5 MMP-3 has a broad substrate specificity for extracellular matrix components, and is able to activate other MMP proenzymes such as proMMP-1, proMMP-9 and proMMP-13. We and others have shown that the serum level of proMMP-3 is elevated in patients with RA, both in early and established disease, and is associated with disease activity and/or joint damage. [6] [7] [8] [9] We have also shown that circulating levels of proMMP-3 are elevated in patients carrying the HLA-DRB1 shared epitope (SE), 9 a conserved amino-acid sequence (QKRAA, QRRAA or RRRAA) encoded by DRB1 alleles associated with susceptibility to RA. 10 An understanding of the factors influencing the production of MMP-3 may allow better identification of patients at risk of developing destructive disease. A polymorphism in the promoter region of the MMP-3 gene on chromosome 11q22 has been identified. 11 This polymorphism is bi-allelic with one variant containing a run of six adenosines (6A) while the other has five (5A). The 6A allele has about half the promoter strength of the 5A allele and is associated with lower MMP-3 expression. 12 Promoter activity has been shown to be modulated by the zinc-finger transcription factor ZBP-89. 13 A recent prospective study on the MMP-3 5A/6A promoter polymorphism indicated that the 6A allele is associated with greater progression of radiographic damage in early RA patients followed up for 4 years. 14 In the current study, we have investigated a large cohort of well-characterised RA patients with established disease (5 þ years) to determine whether this MMP-3 polymorphism is associated with long-term joint damage and functional impairment in RA (Table 1) .
Results and discussion
No significant differences were found among MMP-3 genotypes for Larsen (P ¼ 0. 06) or Health Assessment Questionnaire (HAQ) (P ¼ 0.2) scores, although there was a trend towards higher scores in the MMP-3 6A/6A genotype ( Table 2) . Comparison of the 6A/6A genotype with the combined 5A/5A and 5A/6A genotypes revealed a significantly higher Larsen score in the MMP-3 6A/6A genotype (109.8 vs 91.1, P ¼ 0.04), after correction for disease duration. The trend was similar for the HAQ score although was not statistically significant. The association of MMP-3 6A/6A with Larsen score remained significant (P ¼ 0.012) after inclusion of rheumatoid factor status (P ¼ 0.01) in the ANCOVA. Our results on radiographic damage are similar to those in a recent prospective study on a smaller number (n ¼ 103) of Caucasian patients with early disease. 14 There was a significant difference in the serum levels of proMMP-3 between patients with different MMP-3 genotypes (P ¼ 0.002, Kruskal-Wallis test). A trend (Cuzick test) towards increasing levels across the three genotypes was found (P ¼ 0.001), with the highest levels in the 6A/6A genotype (Table 3) . These results are paradoxical, given that the 6A allele has been associated with lower transcriptional activity. 12 It is possible that cell type differences in genotype-related expression are responsible for this anomaly, or that other factors are more important in determining the amounts of circulating MMP-3.
The overall frequency of the MMP-3 6A/6A genotype in patients carrying an SE allele was about three times greater than in patients without an SE allele, although this did not achieve significance (20.2 vs 7.7%, OR ¼ 3.0 (95% CI 0.8-12.9), P ¼ 0.07). Further analysis of the major SE alleles in this population (DRB1*0101, *0401 and *0404) indicated that the greatest likelihood of being homozygous for the MMP-3 6A allele was in patients carrying two HLA-DRB1*0401 alleles. Such patients were 6.5 Â more likely to carry the MMP-3 6A/6A genotype than patients negative for the SE (95% CI 1.2-38.0, P ¼ 0.01).
The possible relationship between homozygosity for the MMP-3 6A allele and carriage of HLA-DRB1*0401 is interesting. However, this finding should be treated with caution since it cannot be explained by genes in linkage disequilibrium, and no obvious functional explanation is available at present.
We also investigated whether homozygosity for the MMP-3 6A allele had any influence on the association of the SE with disease severity and levels of serum proMMP-3. Patients with the SE and the MMP-3 6A/ 6A genotype had a significantly higher Larsen score than SE þ patients without this genotype (112.1 vs 92.9, P ¼ 0.01, corrected for disease duration). Patients with the MMP-3 6A/6A þ /DRB1*0401 combination had the highest Larsen score (113.9), although this was not significantly different from other combinations of SE þ alleles with the MMP-3 6A/6A genotype (data not shown). A similar trend was seen with the HAQ score although the overall differences were not significant. Levels of MMP-3 in the MMP3 6A/6A þ /SE þ group were significantly higher than in all the remaining patients (242.8 vs 180.5 ng/ml, P ¼ 0.02). These data indicate that there may be some additive effect of the SE and the MMP-3 6A/6A genotype on disease severity. The finding of higher serum proMMP-3 levels in patients carrying the SE and the MMP-3 6A/6A genotype is consistent with this genetic combination contributing to All patients were northern European Caucasians resident in north Staffordshire and satisfied the 1987 ACR diagnostic criteria. 20 They were recruited between 1994 and 1998 in a clinic established to monitor the effects of disease-modifying anti-rheumatic drugs. Therapy was administered as clinically indicated. In all, 89% of patients were being treated with one or more DMARDs including hydroxychloroquine, sulphasalazine, gold or methotrexate. Fewer than 5% of patients were being treated with corticosteroids. Joint damage was assessed by two observers scoring X-rays of the hands and feet using the method of Larsen et al. 21 Inter-and intraobserver reliability was assessed as described previously and showed no systematic bias between readings. 22 Functional assessment was carried out using the HAQ. 23 Samples were genotyped by PCR amplification using mutagenic primers described previously 24 (forward primer (À1201 to À1172, mismatch at nucleotide À1173), 5-GGTTCTCCATTCCTTTGATGGGGGGAAAgA-3; reverse primer (À1072 to À1101), 5-CTTCCTGGAATTCACATCACTGCCAC CACT-3). A recognition site for the restriction enzyme Tth111I (GACN/NNGTC) is created in the case of the 5A allele. PCR products were digested with 5 U Tth111I (Promega) for 3 h at 651C, and separated by electrophoresis on 2% agarose gels stained with ethidium bromide. The 6A/6A genotype exhibits an undigested 130 bp band, whereas the 5A/5A genotype exhibits 97 and 32 bp digestion fragments. The 5A/6A genotype displays 130 and 97 bp bands. Differences among genotypes were analysed by analysis of covariance, with outcome (Larsen, HAQ) as the dependent variable and genotype and disease duration as covariates. No significant difference was found among MMP-3 genotypes for Larsen (P ¼ 0.06) or HAQ (P ¼ 0.2) scores. However, the mean Larsen score in patients with 6A/6A was significantly higher than in those lacking this genotype (P ¼ 0.04), after correction for disease duration. 6 Both antibodies used in the assay recognise the proenzyme in preference to the active form of MMP-3.
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Our results on circulating MMP-3 levels differ from those of Constantin et al, 14 who found no difference in MMP-3 levels between MMP-3 genotypes. However, they investigated the association with baseline levels in patients with early RA (mean 6.9 months), whereas the patients in our study had well-established disease (mean 11.0 years). It is possible that the influence of the MMP-3 genotype on serum MMP-3 levels becomes more apparent in established disease. We and others have shown that the level of serum proMMP-3 is associated with radiographic damage scores in patients with established disease. 9 The association of the 6A/6A genotype with higher MMP-3 levels in our patients is thus consistent with its association with increased radiographic damage.
The association between MMP-3 6A/6A and more severe RA is interesting because of the association of this genotype with progression of coronary atherosclerosis. 11, 12, 15 Recent studies have shown that RA is associated with increased cardiovascular mortality due to ischaemic heart disease, and atherosclerosis appears to be accelerated in patients with RA. [16] [17] [18] Arterial wall thickening in RA has been associated with more severe features of the disease, including higher Larsen and HAQ scores. 19 The data presented here suggest a need to examine the relationship between the MMP-3 6A/6A genotype, disease severity and atherosclerosis in RA.
